Research Guides / GLP-1 Research Guide: From a 2-Minute Hormone to a Once-Weekly Drug
9 min readGlucagon-like peptide-1 is one of the most important hormones you've never heard of. It's produced in your intestine every time you eat. It tells your pancreas to release insulin, tells your liver to stop producing glucose, tells your brain you're full, and tells your stomach to slow down. The entire signal — from meal to satiety — takes about two minutes. Then the enzyme DPP-4 destroys it.
That two-minute half-life is the reason GLP-1 existed in textbooks for decades without becoming a drug. Semaglutide is the molecule that solved that problem. Here's how, what the resulting clinical program demonstrated, and what the current state of GLP-1 research actually covers.
Native GLP-1 (7-36) is a 30-amino-acid peptide. It's an incretin — a hormone released from intestinal L-cells in response to food intake. Its effects are exactly what you'd want for treating type 2 diabetes and obesity: glucose-dependent insulin secretion (insulin goes up only when blood sugar is high, reducing hypoglycemia risk), glucagon suppression, delayed gastric emptying, and appetite reduction via central nervous system signaling.
The problem is that dipeptidyl peptidase-4 (DPP-4), an enzyme abundant in blood and tissues, cleaves GLP-1 at the alanine at position 8, inactivating it within roughly two minutes. A peptide with a two-minute half-life can't be a practical drug — you'd need a continuous IV infusion.
The solution was to modify the molecule so that DPP-4 can't cut it and so that it binds to albumin (a large protein in blood), which both protects it from degradation and slows its clearance. Several pharmaceutical companies pursued this approach. Semaglutide, developed by Novo Nordisk, used two modifications:
The result: a half-life of approximately 165 hours — about seven days. That's what enables once-weekly subcutaneous injection (Ozempic, Wegovy). A separate oral formulation (Rybelsus) uses a different approach — co-formulation with SNAC (sodium N-[8-(2-hydroxybenzoyl)amino]caprylate), an absorption enhancer that temporarily opens the gastric mucosa to let the peptide through before the stomach acid and enzymes destroy it. Oral semaglutide requires daily dosing and must be taken fasting.
| Molecule | Half-life | Route | Dosing frequency | Key modification |
|---|---|---|---|---|
| Native GLP-1 | ~2 minutes | Endogenous | Continuous (post-meal) | None |
| Exenatide (Byetta) | ~2.4 hours | Subcutaneous | Twice daily | Synthetic exendin-4 (Gila monster) |
| Liraglutide (Victoza, Saxenda) | ~13 hours | Subcutaneous | Daily | C16 fatty acid chain + Aib8 |
| Semaglutide (Ozempic, Wegovy) | ~165 hours | Subcutaneous | Weekly | C18 fatty acid chain + Aib8 |
| Oral semaglutide (Rybelsus) | ~1 week | Oral | Daily | C18 chain + SNAC absorber |
| Tirzepatide (Mounjaro, Zepbound) | ~5 days | Subcutaneous | Weekly | Dual GLP-1/GIP agonist (C20 chain) |
The Semaglutide Treatment Effect in People with Obesity (STEP) program is the clinical trial series that established semaglutide as a weight-loss drug. It comprises eight trials, each addressing a different population or question.
STEP 1 is the foundational trial: 1,961 adults with obesity or overweight (without diabetes) received either 2.4 mg semaglutide or placebo weekly for 68 weeks, alongside lifestyle intervention. The result: a mean body weight reduction of 14.9% in the semaglutide group versus 2.4% with placebo. Approximately one-third of participants lost more than 20% of their body weight. This was the first time a pharmacological intervention had produced weight loss in this range — far exceeding earlier drugs.
STEP 2 enrolled participants with both type 2 diabetes and obesity, a population that typically loses less weight. The result: 9.6% reduction versus 3.4% with placebo — smaller than STEP 1 but still clinically significant. STEP 3 tested semaglutide as an adjunct to intensive behavioral therapy, producing 16.0% weight loss. STEP 4 examined what happens when the drug is stopped: participants who continued semaglutide maintained their loss; those switched to placebo regained approximately two-thirds of the lost weight over the following year.
| Trial | Population | Duration | Weight loss (semaglutide vs placebo) | Key finding |
|---|---|---|---|---|
| STEP 1 | Obesity/overweight (no T2D) | 68 wks | 14.9% vs 2.4% | First pharmacological agent to approach 15% |
| STEP 2 | Obesity + T2D | 68 wks | 9.6% vs 3.4% | Smaller but significant effect in harder-to-treat population |
| STEP 3 | Obesity + intensive behavioral therapy | 68 wks | 16.0% vs 5.7% | Lifestyle add-on produces incremental benefit |
| STEP 4 | Post-treatment follow-up | 48 wks post-stop | Regained ~2/3 after stopping | Weight regain after discontinuation is substantial |
| STEP 5 | Obesity + obstructive sleep apnea | 68 wks | Significant apnea improvement | Demonstrates obesity-comorbidity benefit |
The SELECT trial (Semaglutide Effects on Cardiovascular Outcomes) ran separately and enrolled 17,604 participants with cardiovascular disease and overweight or obesity (without diabetes). It demonstrated a 20% reduction in major adverse cardiovascular events — the cardiovascular outcome that led to expanded indications and made semaglutide the first weight-loss drug with a proven cardiovascular benefit.
As GLP-1 agonists moved into widespread use, a concern that had been present in the trial data but underemphasized moved to center stage: the composition of the weight being lost.
DEXA (dual-energy X-ray absorptiometry) scans from the STEP 1 trial showed that roughly 25-40% of the total weight lost on semaglutide came from lean tissue — muscle and bone — rather than fat. This proportion is higher than with bariatric surgery (where fat loss predominates) and represents a meaningful concern because muscle mass is metabolically active tissue. Losing muscle slows resting metabolism, which can make weight maintenance harder after stopping the drug and increases the risk of sarcopenia and frailty, particularly in older adults.
The finding doesn't mean semaglutide causes muscle loss in the pathological sense. The absolute lean-mass loss partly reflects the reduced mechanical loading that comes with eating less and moving less (a common early response to appetite suppression). But the proportion is high enough that exercise physiologists and clinicians now routinely recommend resistance training alongside GLP-1 therapy — not as optional lifestyle advice, but as a necessary countermeasure to preserve muscle and bone.
This is also one of the arguments for next-generation molecules like tirzepatide and retatrutide: the GIP component in both may help preserve lean mass during weight loss, though the clinical evidence for this is still emerging.
"GLP-1" no longer refers only to a single hormone or a single drug. It has become a category — and the research landscape has expanded well beyond semaglutide.
Dual agonists. Tirzepatide (Mounjaro, Zepbound) adds GIP receptor activation to GLP-1, producing ~21% weight loss in the SURMOUNT trials — substantially more than semaglutide. This validated the multi-receptor approach and opened the door for triple agonists.
Triple agonists. Retatrutide (GLP-1 + GIP + glucagon) is the most advanced, with Phase 3 data showing up to 28.3% weight loss at 80 weeks. The glucagon component adds energy expenditure and fat oxidation but introduces safety questions. Multiple other triple agonists are in development.
GLP-1 + amylin combinations. CagriSema (semaglutide + cagrilintide, an amylin analog) aims to add a satiety signal that works through a different pathway. Early results were mixed — the combination didn't perform as well as hoped — but the approach remains active.
Non-obesity indications. GLP-1 agonists are being studied for cardiovascular disease (SELECT was just the beginning), chronic kidney disease, Alzheimer's disease, Parkinson's disease, addiction (alcohol, nicotine, food), and inflammatory conditions. The anti-inflammatory effects of GLP-1 receptor activation — and the downstream effects of substantial weight loss — make this a broad and active research frontier.
The compounding and access problem. As demand has outstripped supply, compounded semaglutide has become widespread. FDA has issued multiple warning letters about dosing errors and safety concerns with compounded products. The gap between the approved drug and the grey-market supply chain is itself a public health issue.
| GLP-1 research area | Current status | What's coming |
|---|---|---|
| Approved GLP-1 agonists | Semaglutide, liraglutide, tirzepatide, dulaglutide, others | Broader label expansions |
| Triple agonists | Retatrutide Phase 3; others earlier stage | Potential approval 2027-2028 |
| GLP-1 + amylin | CagriSema mixed results; next-gen amylin combos in development | Could add 3-5% over GLP-1 alone |
| Non-obesity indications | CV benefit proven; kidney benefit established (FLOW trial) | Neurological and addiction trials ongoing |
| Lean-mass preservation | Exercise guidance; GIP agonism hypothesis | Selective muscle-protective agents in preclinical |
Semaglutide is the most thoroughly studied GLP-1 agonist and the reference point against which all newer molecules are measured. The STEP and SELECT trials demonstrated weight loss and cardiovascular outcomes that were genuinely unprecedented for a pharmacological intervention. The engineering that turned a two-minute hormone into a once-weekly drug is a case study in peptide pharmacology.
The lean-mass finding has reshaped how clinicians think about GLP-1 therapy — from "a drug that causes weight loss" to "a drug that causes weight loss that requires active muscle preservation." The post-discontinuation data from STEP 4 (two-thirds of weight regained within a year) has sharpened the question of what happens when treatment ends.
The GLP-1 landscape is moving quickly. Tirzepatide already outperforms semaglutide for weight loss. Retatrutide's Phase 3 data extends the gap further. The question for semaglutide specifically is not whether it works — the evidence is clear — but whether it remains the right starting point as the category evolves.
Read the full research profile on Semaglutide. For the next-generation comparison, see the Retatrutide research guide.
This guide is for educational and research-reference purposes only. It is not medical advice and does not recommend any compound, dose, or protocol. Semaglutide is an FDA-approved medication available by prescription as Ozempic, Wegovy, and Rybelsus. Compounded semaglutide products carry additional risks documented in FDA safety communications. Decisions about any therapy belong with a qualified clinician.
The most-used peptide combinations, what the research actually says, and where to buy — one page, one email.
No spam. Unsubscribe anytime.